Alkermes (ALKS) Competitors

Alkermes (NASDAQ:ALKS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Do analysts rate ALKS or BIIB?

Alkermes presently has a consensus target price of $38.46, suggesting a potential upside of 13.52%. Biogen has a consensus target price of $213.33, suggesting a potential upside of 53.30%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.69
Biogen	0 Sell rating(s)	17 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.43

Is ALKS or BIIB more profitable?

Alkermes has a net margin of 23.57% compared to Biogen's net margin of 16.87%. Alkermes' return on equity of 30.80% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	23.57%	30.80%	19.09%
Biogen	16.87%	14.98%	8.76%

Which has preferable earnings and valuation, ALKS or BIIB?

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.56B	3.54	$367.07M	$2.17	15.61
Biogen	$9.68B	2.11	$1.63B	$11.19	12.44

Does the media favor ALKS or BIIB?

In the previous week, Biogen had 13 more articles in the media than Alkermes. MarketBeat recorded 30 mentions for Biogen and 17 mentions for Alkermes. Alkermes' average media sentiment score of 1.22 beat Biogen's score of 1.16 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	21 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ALKS or BIIB?

Alkermes has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in ALKS or BIIB?

95.2% of Alkermes shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 4.9% of Alkermes shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community believe in ALKS or BIIB?

Biogen received 1115 more outperform votes than Alkermes when rated by MarketBeat users. Likewise, 71.47% of users gave Biogen an outperform vote while only 70.38% of users gave Alkermes an outperform vote.

Company	Underperform	Outperform
Alkermes	Outperform Votes 701 70.38%	Underperform Votes 295 29.62%
Biogen	Outperform Votes 1816 71.47%	Underperform Votes 725 28.53%

Summary

Alkermes beats Biogen on 10 of the 18 factors compared between the two stocks.